Literature DB >> 9872600

Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction.

J Klominek1, B Baskin, D Hauzenberger.   

Abstract

Platelet-derived growth factor BB (PDGF BB) and the PDGF receptor beta are expressed on mesothelioma cells, but their biological function has not yet been defined. In the present study we used Boyden chambers fitted with filters coated with the adhesive matrix proteins fibronectin, laminin, collagen type IV or the nonmatrix adhesive molecule poly-L-lysine (PLL). Mesothelioma cells migrated towards PDGF BB at concentrations ranging from 0.78 to 12.5 ng/ml if matrix proteins were present as adhesive substrates. This migration was integrin dependent since the same cells failed to migrate if the adhesive interactions necessary for migration were provided by molecules other than integrins. Migration of mesothelioma cells on fibronectin, laminin or collagen-type IV in response to PDGF BB was inhibited if the cells were pretreated with blocking antibodies to alpha3beta1 integrin. These findings describe for the first time PDGF BB as a chemoattractant for malignant mesothelioma cells and that collaboration between PDGF receptor beta and integrin alpha3beta1 is necessary for the motile response of these cells to PDGF BB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9872600     DOI: 10.1023/a:1006542301794

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  60 in total

1.  A PDGF receptor domain essential for mitogenesis but not for many other responses to PDGF.

Authors:  J A Escobedo; L T Williams
Journal:  Nature       Date:  1988-09-01       Impact factor: 49.962

2.  Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins.

Authors:  J Klominek; S Sumitran Karuppan; D Hauzenberger
Journal:  Int J Cancer       Date:  1997-09-17       Impact factor: 7.396

3.  Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor.

Authors:  G R Grotendorst; H E Seppä; H K Kleinman; G R Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

4.  Clinical presentation and natural history of benign and malignant mesothelioma.

Authors:  K H Antman
Journal:  Semin Oncol       Date:  1981-09       Impact factor: 4.929

5.  Pathology of human malignant mesothelioma.

Authors:  Y Suzuki
Journal:  Semin Oncol       Date:  1981-09       Impact factor: 4.929

6.  Fibronectin concentrations in pleural effusions of patients with malignant and non-malignant diseases.

Authors:  A Siri; B Carnemolla; S Raffanti; P Castellani; E Balzano; L Zardi
Journal:  Cancer Lett       Date:  1984-02       Impact factor: 8.679

7.  Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling.

Authors:  T Matsui; K Sano; T Tsukamoto; M Ito; T Takaishi; H Nakata; H Nakamura; K Chihara
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

8.  Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.

Authors:  C Boutin; F Rey; J R Viallat
Journal:  Chest       Date:  1995-09       Impact factor: 9.410

9.  Epidermal growth factor enhancement of HSC-1 human cutaneous squamous carcinoma cell adhesion and migration on type I collagen involves selective up-regulation of alpha 2 beta 1 integrin expression.

Authors:  K Fujii; N Dousaka-Nakajima; S Imamura
Journal:  Exp Cell Res       Date:  1995-01       Impact factor: 3.905

10.  Platelet-derived growth factor in chemotactic for fibroblasts.

Authors:  H Seppä; G Grotendorst; S Seppä; E Schiffmann; G R Martin
Journal:  J Cell Biol       Date:  1982-02       Impact factor: 10.539

View more
  17 in total

1.  Mathematical models of the VEGF receptor and its role in cancer therapy.

Authors:  Tomás Alarcón; Karen M Page
Journal:  J R Soc Interface       Date:  2007-04-22       Impact factor: 4.118

2.  Immunological alterations found in mesothelioma patients and supporting experimental evidence.

Authors:  Yoshie Miura; Yasumitsu Nishimura; Megumi Maeda; Shuko Murakami; Hiroaki Hayashi; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

3.  Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.

Authors:  Zhiwen Liu; Julius Klominek
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

4.  A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.

Authors:  Sarita Dubey; Pasi A Jänne; Lee Krug; Herbert Pang; Xiaofei Wang; Robin Heinze; Colleen Watt; Jeff Crawford; Robert Kratzke; Everett Vokes; Hedy Lee Kindler
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

5.  Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Authors:  Anne S Tsao; James Moon; Ignacio I Wistuba; Nicholas J Vogelzang; Gregory P Kalemkerian; Mary W Redman; David R Gandara; Karen Kelly
Journal:  J Thorac Oncol       Date:  2017-06-06       Impact factor: 15.609

6.  Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

Authors:  Thierry Jahan; Lin Gu; Robert Kratzke; Arkadiusz Dudek; Gregory A Otterson; Xiaofei Wang; Mark Green; Everett E Vokes; Hedy Lee Kindler
Journal:  Lung Cancer       Date:  2011-12-22       Impact factor: 5.705

7.  Immunological changes in mesothelioma patients and their experimental detection.

Authors:  Megumi Maeda; Yoshie Miura; Yasumitsu Nishimura; Shuko Murakami; Hiroaki Hayashi; Naoko Kumagai; Tamayo Hatayama; Minako Katoh; Naomi Miyahara; Shoko Yamamoto; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi Otsuki
Journal:  Clin Med Circ Respirat Pulm Med       Date:  2008-03-26

8.  Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.

Authors:  Anne S Tsao; Nusrat Harun; Junya Fujimoto; Vikki Devito; J Jack Lee; Elisabetta Kuhn; Reza Mehran; David Rice; Cesar Moran; Waun Ki Hong; Li Shen; Milind Suraokar; Ignacio Wistuba
Journal:  Ann Diagn Pathol       Date:  2014-02-20       Impact factor: 2.090

9.  PDGF signaling is required for primitive endoderm cell survival in the inner cell mass of the mouse blastocyst.

Authors:  Jérôme Artus; Minjung Kang; Michel Cohen-Tannoudji; Anna-Katerina Hadjantonakis
Journal:  Stem Cells       Date:  2013-09       Impact factor: 6.277

10.  Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.

Authors:  Marya F McCarty; Ray J Somcio; Oliver Stoeltzing; Jane Wey; Fan Fan; Wenbiao Liu; Corazon Bucana; Lee M Ellis
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.